Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

2.

Rational Combinations of Targeted Agents in AML.

Bose P, Grant S.

J Clin Med. 2015 Apr 10;4(4):634-64. doi: 10.3390/jcm4040634. eCollection 2015 Apr. Review.

3.

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S.

Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11.

4.

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Bucur O, Stancu AL, Goganau I, Petrescu SM, Pennarun B, Bertomeu T, Dewar R, Khosravi-Far R.

PLoS One. 2013 Oct 14;8(10):e77390. doi: 10.1371/journal.pone.0077390. eCollection 2013.

5.

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.

Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2013 May;14(5):458-65. doi: 10.4161/cbt.24424.

6.

The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S.

Mol Cancer Ther. 2013 Jun;12(6):878-89. doi: 10.1158/1535-7163.MCT-12-0902. Epub 2013 Mar 27.

7.

Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P.

Mol Pharmacol. 2012 Aug;82(2):322-32. doi: 10.1124/mol.112.078907. Epub 2012 May 17.

8.

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W Sr, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1657-67. doi: 10.1007/s00280-012-1839-5. Epub 2012 Feb 15.

9.

Enhancing CHK1 inhibitor lethality in glioblastoma.

Tang Y, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2012 Apr;13(6):379-88. doi: 10.4161/cbt.19240. Epub 2012 Apr 1.

10.

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S.

Blood. 2011 Nov 10;118(19):5189-200. doi: 10.1182/blood-2011-02-339432. Epub 2011 Sep 12.

11.

Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma.

Dai B, Zhao XF, Mazan-Mamczarz K, Hagner P, Corl S, Bahassi el M, Lu S, Stambrook PJ, Shapiro P, Gartenhaus RB.

Nat Commun. 2011 Jul 19;2:402. doi: 10.1038/ncomms1404.

12.

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.

Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2011 Aug 1;12(3):215-28. Epub 2011 Aug 1.

13.

CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S.

Mol Interv. 2011 Apr;11(2):133-40. doi: 10.1124/mi.11.2.11. Review.

14.

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.

Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.

Br J Haematol. 2011 Apr;153(2):222-35. doi: 10.1111/j.1365-2141.2011.08591.x. Epub 2011 Mar 6.

15.

Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.

Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S.

Blood. 2011 Feb 10;117(6):1947-57. doi: 10.1182/blood-2010-06-291146. Epub 2010 Dec 10.

16.

PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Dudgeon C, Wang P, Sun X, Peng R, Sun Q, Yu J, Zhang L.

Mol Cancer Ther. 2010 Nov;9(11):2893-902. doi: 10.1158/1535-7163.MCT-10-0635. Epub 2010 Oct 26.

17.

Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.

Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, Dent P.

Mol Pharmacol. 2010 Nov;78(5):909-17. doi: 10.1124/mol.110.067199. Epub 2010 Aug 9. Erratum in: Mol Pharmacol. 2011 Jan;79(1):207-9.

18.

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S.

Leuk Res. 2010 Mar;34(3):379-86. doi: 10.1016/j.leukres.2009.07.013. Epub 2010 Feb 1.

19.

New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Dai Y, Grant S.

Clin Cancer Res. 2010 Jan 15;16(2):376-83. doi: 10.1158/1078-0432.CCR-09-1029. Epub 2010 Jan 12. Review.

20.

The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.

Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S.

Blood. 2009 Nov 12;114(20):4507-16. doi: 10.1182/blood-2008-09-177881. Epub 2009 Sep 22.

Supplemental Content

Support Center